# US 2018/0021450 A1 · Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021450 A1
- Document ID: US20180021450A1
- Status: Published application
- Kind: A1
- Application number: 15/611,985
- Filed: 2017-06-02
- Published: 2018-01-25
- Earliest claimed: 2014-12-03
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Eric Brown; Wouter Hazenbos; Isidro Hotzel; Kimberly Kajihara; Sophie M. Lehar; Sanjeev Mariathasan; Thomas Pillow; Leanna Staben; Vishal Verma; Binqing Wei; Min Xu
- Web page: https://patentgrep.com/patent/US20180021450A1

## CPC

- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 39/40: bacterial
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6835: {the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site}
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.

## Claims

### Claim 1

An antibody-antibiotic conjugate compound comprising an anti-wall teichoic acid (WTA) monoclonal antibody, wherein the anti-wall teichoic acid monoclonal antibody binds to Staphylococcus aureus, and covalently attached by a protease-cleavable, non-peptide linker to a rifamycin-type antibiotic, the antibody-antibiotic conjugate compound having the formula:
Ab-(PML-abx)p
wherein:
Ab is the anti-wall teichoic acid antibody:
PML is the protease-cleavable, non-peptide linker having the formula:
-Str-PM-Y-
where Str is a stretcher unit: PM is a peptidomimetic unit, and Y is a spacer unit;
abx is the rifamycin-type antibiotic; and
p is an integer from 1 to 8.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 wherein the rifamycin-type antibiotic comprises a quaternary amine attached to the protease-cleavable, non-peptide linker.

### Claim 5 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 having Formula I:
wherein:
the dashed lines indicate an optional bond;
R is H, C1-C12 alkyl, or C(O)CH3;
R1 is OH;
R2 is CH═N-(heterocyclyl), wherein the heterocyclyl is optionally substituted with one or more groups independently selected from C(O)CH3, C1-C12 alkyl, C1-C12 heteroaryl, C2-C20 heterocyclyl, C6-C20 aryl, and C3-C12 carbocyclyl;
or R1 and R2 form a five- or six-membered fused heteroaryl or heterocyclyl, and optionally forming a spiro or fused six-membered heteroaryl, heterocyclyl, aryl, or carbocyclyl ring, wherein the spiro or fused six-membered heteroaryl, heterocyclyl, aryl, or carbocyclyl ring is optionally substituted H, F, Cl, Br, I, C1-C12 alkyl, or OH;
PML is the protease-cleavable, non-peptide linker attached to R2 or the fused heteroaryl or heterocyclyl formed by R1 and R2; and
Ab is the anti-wall teichoic acid (WTA) antibody.

### Claim 6 (depends on 5)

The antibody-antibiotic conjugate compound of claim 5 having the formula:
wherein
R3 is independently selected from H and C1-C12 alkyl;
n is 1 or 2;
R4 is selected from H, F, Cl, Br, I, C1-C12 alkyl, and OH; and
Z is selected from NH, N(C1-C12 alkyl), O and S.

### Claim 7 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 selected from the formulas:
wherein
R5 is selected from H and C1-C12 alkyl; and
n is 0 or 1.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 having the formula:
wherein
R3 is independently selected from H and C1-C2 alkyl; and
n is 1 or 2.

### Claim 11 (depends on 10)

The antibody-antibiotic conjugate compound of claim 10 having the formula:

### Claim 12 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 wherein Str has the formula:
wherein R6 is selected from the group consisting of C1-C12 alkylene, C1-C12 alkylene-C(═O), C1-C12 alkylene-NH, (CH2CH2O)r, (CH2CH2O)r—C(═O), (CH2CH2O)r—CH2, and C1-C12 alkylene-NHC(═O)CH2CH(thiophen-3-yl), where r is an integer ranging from 1 to 10.

### Claim 13 (depends on 12)

The antibody-antibiotic conjugate compound of claim 12 wherein R6 is (CH2)5.

### Claim 14 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 wherein PM has the formula:
where R and R8 together form a C3-C7 cycloalkyl ring, and
AA is an amino acid side chain selected from H, —CH3, —CH2(C6Hs), —CH2CH2CH2CH2NH2, —CH2CH2CH2NHC(NH)NH2, —CHCH(CH3)CH3, and —CH2CH2CH2NHC(O)NH2.

### Claim 15 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 wherein Y comprises para-aminobenzyl or para-aminobenzyloxycarbonyl.

### Claim 16 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 having the formula:

### Claim 17 (depends on 16)

The antibody-antibiotic conjugate compound of claim 16 having the formula:

### Claim 18 (depends on 15)

The antibody-antibiotic conjugate compound of claim 15 having the formula:

### Claim 19 (depends on 18)

The antibody-antibiotic conjugate compound of claim 18 having the formula:

### Claim 20 (depends on 15)

The antibody-antibiotic conjugate compound of claim 15 selected from the formulas:

### Claim 21 (depends on 16)

The antibody-antibiotic conjugate compound of claim 16 selected from the formulas:

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The antibody-antibiotic conjugate of claim 1 wherein the anti-wall teichoic acid (WTA) monoclonal antibody is an isolated monoclonal antibody comprising a light (L) chain and a heavy (H) chain, the L chain comprising CDR L1, CDR L2, and CDR L3 and the H chain comprising CDR H1, CDR H2 and CDR H3, wherein the CDR L1, CDR L2, and CDR L3 and CDR H1, CDR H2 and CDR H3 comprise the amino acid sequences of the CDRs of each of Abs 4461 (SEQ ID NO. 1-6), 4624 (SEQ ID NO. 7-12), 4399 (SEQ ID NO. 13-18), and 6267 (SEQ ID NO. 19-24) respectively, as shown in Tables 1A and 1B.

### Claim 24 (depends on 1)

The antibody-antibiotic conjugate of claim 1 wherein the anti-wall teichoic acid (WTA) antibody comprises a heavy chain variable region (VH), wherein the VH comprises at least 95% sequence identity over the length of the VH region selected from the VH sequence of SEQ ID NO.26, SEQ ID NO.28, SEQ ID NO.30, SEQ ID NO.32 of antibodies 4461, 4624, 4399, and 6267, respectively.

### Claim 25 (depends on 24)

The antibody-antibiotic conjugate of claim 24, further comprising a L chain variable region (VL) wherein the VL comprises at least 95% sequence identity over the length of the VL region selected from the VL sequence of SEQ ID NO.25, SEQ ID NO.27, SEQ ID NO.29, SEQ ID NO.31 of antibodies 4461, 4624, 4399, and 6267, respectively.

### Claim 26 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1, wherein the antibody is an anti-WTAβ monoclonal antibody.

### Claim 27 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the anti-WTAβ antibody comprises a light chain and a H chain, the L chain comprising CDR L1, CDR L2, and CDR L3 and the H chain comprising CDR H1, CDR H2 and CDR H3, wherein the CDR L1, CDR L2, and CDR L3 and CDR H1, CDR H2 and CDR H3 comprise the amino acid sequences of the corresponding CDRs of each of Abs shown in FIG. 12 (SEQ ID NO. 33-110).

### Claim 28 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the anti-WTAβ antibody comprises a L chain variable region (VL) wherein the VL comprises at least 95% sequence identity over the length of the VL region selected from the VL sequence corresponding to each of the antibodies 6078, 6263, 4450, 6297, 6239, 6232, 6259, 6292, 4462, 6265, 6253, 4497, and 4487 respectively, as shown in FIG. 15A-1, 15A-2, 15A-3 at Kabat positions 1-107.

### Claim 29 (depends on 28)

The antibody-antibiotic conjugate compound of claim 28, wherein the anti-WTAβ antibody further comprises a heavy chain variable region (VH), wherein the VH comprises at least 95% sequence identity over the length of the VH region selected from the VH sequences corresponding to each of the antibodies 6078, 6263, 4450,6297, 6239, 6232, 6259, 6292, 4462, 6265, 6253, 4497, and 4487 respectively, as shown in FIG. 15B-1 to 15B-6 at Kabat positions 1-113.

### Claim 30 (depends on 29)

The antibody-antibiotic conjugate compound of claim 29, wherein the VL comprises the sequence of SEQ ID NO. 111 and the VH comprises the sequence of SEQ ID NO. 112 wherein X is Q or E and X1 is M, I or V.

### Claim 31 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the antibody light chain contains an engineered cysteine and comprises the sequence of SEQ ID NO. 115 and the H chain comprises the SEQ ID NO. 116 wherein X is M, I or V.

### Claim 32 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the antibody light chain comprises the sequence of SEQ ID NO. 113 and the H chain contains an engineered cysteine and comprises the SEQ ID NO. 117 wherein X is M, I or V.

### Claim 33 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the antibody light chain contains an engineered cysteine and comprises the sequence of SEQ ID NO. 115, and the H chain contains an engineered cysteine and comprises the SEQ ID NO. 117 wherein X is M, I or V.

### Claim 34 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the anti-WTAβ antibody comprises a VH and a VL, wherein the VH comprises at least 95% sequence identity over the length of the VH of SEQ ID NO. 156 and the VL comprises at least 95% sequence identity over the length of the VL of sequence SEQ ID NO. 119.

### Claim 35 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the anti-WTAβ antibody comprises a VH comprising the sequence of SEQ ID NO. 156 and a VL comprising the sequence of the SEQ ID NO. 119.

### Claim 36 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the anti-WTAβ antibody comprises a L chain comprising the sequence of SEQ ID NO.121 and a H chain comprising the sequence of SEQ ID NO. 124.

### Claim 37 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the anti-WTAβ antibody comprises a L chain comprising the sequence of SEQ ID NO. 123 and a H chain comprising the sequence of SEQ ID NO. 157

### Claim 38 (depends on 26)

The antibody-antibiotic conjugate compound of claim 26, wherein the anti-WTAβ antibody comprise a L chain comprising the sequence of SEQ ID NO. 123 and a H chain comprising the sequence of SEQ ID NO. 124.

### Claim 39 (depends on 1)

The antibody-antibiotic conjugate compound of claim 1 wherein the antibody comprises: i) L chain and H chain CDRs of SEQ ID NOs 99-104 or the L chain and H chain CDRs of SEQ ID NOs. 33-38; or ii) the VL of SEQ ID NO.119 or SEQ ID NO. 123 paired with the VH of SEQ ID NO.120 or SEQ ID NO. 156; or iii) the VL of SEQ ID NO.111 paired with the VH of SEQ ID NO.112.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42 (depends on 1)

A pharmaceutical composition comprising the antibody-antibiotic conjugate compound of claim 1, and a pharmaceutically acceptable carrier, glidant, diluent, or excipient.

### Claim 43 (depends on 1)

A method of treating a bacterial infection in a patient comprising administering to the patient a therapeutically-effective amount of the antibody-antibiotic conjugate compound of claim 1, wherein the bacterial infection is a Staphylococcus aureus infection.

### Claim 44 (depends on 1)

A method of killing intracellular Staph aureus in the cells of a staph aureus infected patient without killing the host cells by administering an anti-WTA-antibiotic conjugate of claim 1.

### Claim 45 (depends on 1)

A process for making the antibody-antibiotic conjugate compound of claim 1 comprising conjugating a rifamycin-type antibiotic to an anti-wall teichoic acid (WTA) antibody.

### Claim 46 (depends on 23)

A kit for treating a bacterial infection, comprising:
a) the pharmaceutical composition of claim 23; and
b) instructions for use.

### Claim 47

An antibiotic-linker intermediate having Formula II:
wherein:
the dashed lines indicate an optional bond;
R is H, C1-C12 alkyl, or C(O)CH3;
R1 is OH;
R2 is CH═N-(heterocyclyl), wherein the heterocyclyl is optionally substituted with one or more groups independently selected from C(O)CH3, C1-C12 alkyl, C1-C12 heteroaryl, C2-C20 heterocyclyl, C6-C20 aryl, and C3-C12 carbocyclyl;
or R1 and R2 form a five- or six-membered fused heteroaryl or heterocyclyl, and optionally forming a spiro or fused six-membered heteroaryl, heterocyclyl, aryl, or carbocyclyl ring, wherein the spiro or fused six-membered heteroaryl, heterocyclyl, aryl, or carbocyclyl ring is optionally substituted H, F, Cl, Br, I, C1-C12 alkyl, or OH;
PML is a protease-cleavable, non-peptide linker attached to R2 or the fused heteroaryl or heterocyclyl formed by R1 and R2, and having the formula:
-Str-PM-Y-
where Str is a stretcher unit; PM is a peptidomimetic unit, and Y is a spacer unit; and
X is a reactive functional group selected from maleimide, thiol, amino, bromide, bromoacetamido, iodoacetamido, p-toluenesulfonate, iodide, hydroxyl, carboxyl, pyridyl disulfide, and N-hydroxysuccinimide.

### Claim 48 (depends on 47)

The antibiotic-linker intermediate of claim 47 wherein X is

### Claim 49 (depends on 47)

The antibiotic-linker intermediate of claim 47 having the formula:
wherein
R3 is independently selected from H and C1-C12 alkyl;
n is 1 or 2;
R4 is selected from H, F, Cl, Br, I, C1-C12 alkyl, and OH; and
Z is selected from NH, N(C1-C12 alkyl), O and S.

### Claim 50 (depends on 47)

The antibiotic-linker intermediate of claim 47 having the formula:

### Claim 51 (depends on 47)

The antibiotic-linker intermediate of claim 47 selected from the formulas:

### Claim at position 52

52-54. (canceled)

### Claim 55 (depends on 23)

The antibody-antibiotic conjugate compound of claim 23, wherein the VL of the anti-WTA monoclonal antibody comprises-CDR L1 comprising the sequence of KSSQSIFRTSRNKNLLN (SEQ ID NO:99), CDR L2 comprising the sequence of WASTRKS (SEQ ID NO: 100), and CDR L3 comprising the sequence of QQYFSPPYT (SEQ ID NO: 101); and the VH of the anti-WTA monoclonal antibody comprises CDR H1 comprising the sequence of SFWMH (SEQ ID NO: 102), CDR H2 comprising the sequence of FTNNEGTTTAYADSVRG (SEQ ID NO: 103), and CDR H3 comprising the sequence of GEGGLDD (SEQ ID NO: 118) or GDGGLDD (SEQ ID NO: 104).
